We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+10.75%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$888M
AUM Growth
+$138M
Cap. Flow
-$23.2M
Cap. Flow %
-2.62%
Top 10 Hldgs %
78.6%
Holding
52
New
13
Increased
8
Reduced
4
Closed
22

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$28.5M
2
MGNX icon
MacroGenics
MGNX
+$21.3M
3
IMDZ
Immune Design Corp.
IMDZ
+$19.4M
4
ARRY
Array Biopharma Inc
ARRY
+$18.6M
5
APLS
Apellis Pharmaceuticals
APLS
+$16.8M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$40M
2
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$21.3M
3
FBRX icon
Forte Biosciences
FBRX
+$18.7M
4
CTMX icon
CytomX Therapeutics
CTMX
+$15.1M
5
INDP icon
Indaptus Therapeutics
INDP
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 83.97%
2 Miscellaneous 16.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
26
Madrigal Pharmaceuticals
MDGL
$12.3B
$3.21M 0.36%
+35,000
New +$2M
DNLI icon
27
Denali Therapeutics
DNLI
$3.84B
$3.13M 0.35%
+200,000
New +$3.59M
XNCR icon
28
Xencor
XNCR
$1.94B
$2.48M 0.28%
112,976
+22,862
+25% +$496K
MRTX
29
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.88M 0.21%
+103,240
New +$1.6M
NTLA icon
30
CALL
Intellia Therapeutics
NTLA
$1.8B
$1.44M 0.16%
+75,000
New +$1.73M
ACRS icon
31
Aclaris Therapeutics
ACRS
$885M
– –
-60,000
Closed -$1.55M
ADVM
32
DELISTED
Adverum Biotechnologies
ADVM
– –
-76,295
Closed -$2.79M
BMY icon
33
Bristol-Myers Squibb
BMY
$136B
– –
-17,060
Closed -$1.09M
CTMX icon
34
CytomX Therapeutics
CTMX
$699M
– –
-829,771
Closed -$15.1M
FATE icon
35
Fate Therapeutics
FATE
$291M
– –
-2,262,678
Closed -$8.96M
FBRX icon
36
Forte Biosciences
FBRX
– –
-4,006
Closed -$18.7M
INDP icon
37
Indaptus Therapeutics
INDP
$152M
– –
-670
Closed -$13.4M
INSM icon
38
Insmed
INSM
$25.9B
– –
-405,400
Closed -$12.7M
OMER icon
39
Omeros
OMER
$1.35B
– –
-450,000
Closed -$9.73M
RGLS
40
DELISTED
Regulus Therapeutics
RGLS
– –
-43,660
Closed -$6.55M
SGMO
41
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-222,388
Closed -$3.34M
TPST icon
42
Tempest Therapeutics
TPST
$17.5M
– –
-1,201
Closed -$4.99M
VRTX icon
43
CALL
Vertex Pharmaceuticals
VRTX
$137B
– –
-67,600
Closed -$10.3M
ZLAB icon
44
Zai Lab
ZLAB
$2.93B
– –
-159,535
Closed -$4.31M
SYRS
45
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-10,400
Closed -$1.53M
DCPH
46
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-45,000
Closed -$855K
MRNS
47
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-905,568
Closed -$21.3M
SGEN
48
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-30,000
Closed -$1.63M
FSTX
49
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-4,000
Closed -$269K
CLVS
50
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-25,765
Closed -$2.12M
1
2
3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2017 Portfolio in Review

As of Q4 2017, EcoR1 Capital held 52 positions worth $888M, up 18% from $750M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

EcoR1 Capital's Q4 2017 filing shows 13 new, 8 increased, 4 reduced and 22 closed positions. Its largest new stake was MacroGenics: 1,140,794 shares worth $21.7M. The largest sale was Immunomedics Inc, an estimated $40M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 97% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q4 2017 buy was MacroGenics: 1,140,794 shares worth $21.7M.
  • EcoR1 Capital added most to Dicerna Pharmaceuticals, Inc. in Q4 2017, an estimated $28.5M increase.
  • EcoR1 Capital's biggest Q4 2017 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $12.3M.
  • EcoR1 Capital fully exited Immunomedics Inc in Q4 2017, selling an estimated $40M.
  • EcoR1 Capital's ten largest holdings make up 79% of its $888M portfolio in Q4 2017.
  • EcoR1 Capital opened 13 new positions and closed 22 in Q4 2017.
  • EcoR1 Capital's portfolio value rose 18% quarter-over-quarter to $888M.

Based on EcoR1 Capital's 13F filing for Q4 2017, filed 14 Feb 2018.